

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 6, 2007

Signature: *Lenay Rogers*

(Lenay Rogers)

Patent

Docket No. 529282002300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michelle Leanne STYLES et al.

Serial No.: 10/585,916

Filing Date: (Int'l) January 12, 2005

For: SELECTIVE KINASE INHIBITORS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

The documents numbered 1 and 2 listed on the attached Form PTO/SB/08a/b were cited in an International Search Report mailed on March 17, 2005, directed to a counterpart international or foreign application and have not been previously cited.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling;
or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 529282002300.

Dated: March 6, 2007

Respectfully submitted,

By 
Laurie L. Hill
Registration No.: 51,804
MORRISON & FOERSTER LLP
12531 High Bluff Drive
Suite 100
San Diego, California 92130-2040
(858) 720-7945

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/585,916
				Filing Date	(Int'l) January 12, 2005
				First Named Inventor	Michelle Leanne STYLES
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	529282002300

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	1.	WO-01/000213	01/2001	Merck		
	2.	WO-03/099811	12/2003	Cytosia Ltd		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3.	DISCAFANI et al., Biochem. Pharmacol. (1999) 57:917-925	
	4.	FINET et al., Curr. Org. Chem. (2002) 6:597-626	
	5.	FRY et al., PNAS USA (1998) 95:12022-12027	
	6.	HOVENS et al., PNAS USA (1992) 89:11818-11822	
	7.	International Search Report for PCT/AU2005/000022, mailed on March 17, 2005, 3 pages	
	8.	KOZMA et al., EMBO J. (1988) 7:147-154	
	9.	KUMADA et al., Org. Synth. Coll. (1988) 6:407	
	10.	LEVITZKI, Top. Curr. Chem. (2000) 211:1-15	
	11.	MIYARA and SUZUKI, Chem. Rev. (1995) 95:2457	
	12.	NEGISHI, J. Organomet. Chem. (2002) 653:34-40	
	13.	RUSSELL et al., Science (1995) 270:797-800	
	14.	SADOWSKI et al., Mol. Cell Biol. (1986) 6:4396-4408	
	15.	SMALL et al., J. Med. Chem. (1999) 42:1803-1815	
	16.	SMALL et al., J. Med. Chem. (2000) 43:1380-1397	
	17.	SMALL et al., J. Med. Chem. (2001) 44:429-440	
	18.	SPIOTTO and CHUNG, Prostate (2000) 42:88-98	
	19.	STILLE, Angew. Chem. Int. Ed. Engl. (1986) 25:508	
	20.	TSOU et al., J. Med. Chem. (2001) 44:2719-2734	
	21.	WILKS and KURBAN, Oncogene (1988) 3:289-294	
	22.	WILKS et al., Mol. Cell Biol. (1991) 11:2057-2065	
	23.	WISSNER et al., J. Med. Chem. (2003) 46:49-63	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

sd- 327534